«We anticipate,» says Dr. Chou, «that this research will provide important pre-clinical data to support clinical trials using DAC and similar drugs combined with immune therapies targeting antigens like NY - ESO - 1 to treat advanced colorectal cancer and
potentially other common cancers.»
Hospital and other health care costs for prostate, breast, liver colorectal, lung and
other common cancers cost San Franciscans about $ 213 million annually.
Tulane University researchers have discovered that the protein PHLDB3, thought to be a potential tumor suppressor, actually allows cancer cells to thrive in pancreatic, prostate, colon, breast, lung, and
other common cancers.
One of the most intriguing findings comes from a comparison of breast cancer subtypes to
other common cancers.
The incidence of the lymphoid cancers is rising faster than
any other common cancer seen in North America.